NCT07223671

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Repotrectinib	Specified dose on specified days
DRUG	Metformin	Specified dose on specified days
DRUG	Digoxin	Specified dose on specified days
DRUG	Rosuvastatin	Specified dose on specified days
DRUG	Bupropion	Specified dose on specified days
DRUG	Flurbiprofen	Specified dose on specified days
DRUG	Omeprazole	Specified dose on specified days

Timeline

• Start date: 2025-12-31
• Primary completion: 2026-02-19
• Completion: 2026-03-19
• First posted: 2025-11-03
• Last updated: 2026-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study